我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

卡维地洛对糖尿病并发冠心病心力衰竭患者的影响(PDF)

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2007年第1期
页码:
70-73
栏目:
临床研究
出版日期:
2007-01-01

文章信息/Info

Title:
Effect of Carvedilol in patients with heart failure due to type 2 diabetes mellitus and coronary heart disease
作者:
吴娜1;  王修卫2
1.青岛市市立医院心内科, 山东 青岛 266001； 2.青岛市第八人民医院
Author(s):
WU Na;  WANG Xiuwei
Department of Cardiology, Qingdao Municipal Hospital, Qingdao 266001，Shandong, China
关键词:
卡维地洛;  心力衰竭;  糖尿病;  冠状动脉疾病;  血脂
Keywords:
carvedilol;  heart failure;  diabetes mellitus;  coronary disease;  bloodlipoids
分类号:
R541.6;R587.1
DOI:
-
文献标识码:
A
摘要:
目的 观察卡维地洛对2型糖尿病并发冠心病心力衰竭患者的心功能及血脂、血糖、胰岛素抵抗的影响。 方法 2型糖尿病并发冠心病心力衰竭患者105例，根据常规治疗基础上加用卡维地洛与否分为治疗组和对照组。治疗12个月，观察卡维地洛对心功能及血脂、血糖、胰岛素抵抗的指标变化。 结果 ①卡维地洛用量平均(12±4)mg/d。②对心功能及心室重构的影响：与对照组相比，治疗组12个月左室射血分数较对照组显著升高［（50±4）%与（45±6）%，P<0.01］，左室收缩末容积下降［(166±41）ml与（184±38）ml，P<0.01］。NYHA分级也明显改善。③治疗12个月后治疗组与对照组血脂及空腹血糖、胰岛素、胰岛素抵抗指数均无明显变化。 结论 卡维地洛能明显改善2型糖尿病并发冠心病心力衰竭患者的心功能和心室重构，而对其血脂及空腹血糖、胰岛素、胰岛素抵抗指数无明显影响，可以安全应用于2型糖尿病并发冠心病心力衰竭患者。
Abstract:
AIM To study the effect of Carvedilol in patients with heart failure due to type 2 diabetes mellitus and coronary heart disease. METHODS One hundred and five patients were divided into treatment group (with Carvedilol) and control group (without Carvedilol) and the changes of Carvedilol on left ventricular function, bloodlipoids, concentration of fast plasma glucose(FPG), fast insulins (FNS) and HOMAIR were observed. RESULTS The average dose of Carvedilol was (12±4)mg/d and the patients in treatment group had better results than those in control group according to NYHA function class after 12 months′ treatment. During followup, the LVEF at 12 months increased by （50±4）% in the Carvedilol group compared with the control group（45±6）% (P<0.01) and LVESV reduced by (166±41)ml in the Carvedilol group compared with that in the control group (184±38)ml (P<0.01). There was no significant change in bloodlipoids, concentration of FPG, FNS and HOMAIR after 12 months′ treatment. CONCLUSION Carvedilol can improve the left ventricular function and remodeling in patients with heart failure due to type 2 diabetes mellitus and coronary heart disease and has no influence on bloodlipoids, concentration of FPG FNS and HOMAIR.

参考文献/References

［1］Beckman JA, Creager MA, Libby P. Diabetes and artherosclerosis: epidemiology , pathophysiology, and management［J］. JAMA, 2002, 287（19）: 2570-2581.

［2］李小鹰. 冠心病合并糖尿病时的心力衰竭［J］.中华内科杂志，2004,43(3):231-233.

［3］钱立荣. 关于糖尿病的新诊断标准与分型［J］.中国糖尿病杂志,2000，8（1）：5-6.

［4］Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and betacell function from fasting plasma glucose and insulin concentrations in man ［J］. Diabetalogia, 1985, 28（7）: 412-419.

［5］AustraliaNew Zealand Heart Failure Resarch Collaborative Group. Effects of carvedilol, a vasodilatorβblocker, in patients with congestive heart failure due to ischemic heart disease［J］. Circulation ,1995,92(2):213-218.

［6］Kurz T, Richard D, Gorge B, et al. Differential effects of carvedilol on norepinephrine release in normal and ischemic heart［J］. J Cardiovasc Pharmacol, 2000,36(1):96-100.

［7］Cargnoni A, Ceconi C, Bernocchi P, et al. Reduction of oxidative stress by carvedilol: role in maintenance of ischemic myocardium viability ［J］. Cardiovasc Res, 2000,47(3):556-566.

［8］Jacob s, Balletshofer B, Henriksen E J, et al. Betablocking agents in patients with insulin resistance: effects of vasodilating betablockers［J］. Blood Press, 1999, 8(5-6):261-268.

［9］Bakris GL, Fonseca V, Katholi RE, et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial［J］. JAMA, 2004, 292(18): 2227-2236.

［10］Krum H, Roecker EB, Mohacsi P, et al. Effects of initiating Carvedilol in patients with severe chronic heart failure: results from the COPERNICUS study ［J］. JAMA, 2003, 289(6):712-718.

［11］Jonas M,ReicherReiss H, Boyko V, et al. Usefulness of betablocker therapy in patients with noninsulindependent diabetes mellitus and coronary artery disease. Bezafibrate Infarction Prevention (BIP) Study Group［J］. Am J Cardiol, 1996,77(15):1273-1277.

［12］Noguchi N,Nishino K,Niki E.Antioxidant action of the antihypertensive drug,carvedilol,against lipid peroxidation［J］. Biochem Pharmacol, 2000, 59(9):1069-1076.

备注/Memo

备注/Memo:
收稿日期：2005-10-24.作者简介：吴娜，硕士，主治医师Email：wuna@medmail.com.cn
更新日期/Last Update: